Biogen (BIIB) Reports Topline Phase 3 Results of Tofersen and its Open-Label Extension in SOD1-ALS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq futures surge 2% as chip outlook calms AI jitters; inflation data awaited
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Long-term Prospects for Biogen’s (BIIB) Aduhelm Remain Key Question - Analyst
October 20, 2021 8:21 AM EDTEarlier today, Biogen (NASDAQ: BIIB) reported Q3 results: EPS of $4.77, $0.66 better than the analyst estimate of $4.11; revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.
The company also updated its full-year guidance: EPS of $18.85-$19.35, versus the consensus of $18.61; FY2021... More
Biogen (BIIB) October weekly option implied volatility flat into the expected release of quarter
October 15, 2021 4:45 AM EDTBiogen (NASDAQ: BIIB) October weekly call option implied volatility is at 42, November is at 39; compared to its 52-week range of 32 to 121 into the expected release of quarter results before the bell on October 20.
... MoreBiogen (BIIB) PT Lowered to $344 at Stifel
October 14, 2021 5:11 PM EDTStifel analyst Paul Matteis lowered the price target on Biogen (NASDAQ: BIIB) to $344.00 (from $430.00) while maintaining a Buy rating.
The analyst commented, "Biogen has pulled in 35%-40% off highs, some of which we believe is deserved. The Aduhelm NCD review has... More
Biogen (BIIB) PT Lowered to $327 at Cantor Fitzgerald
October 14, 2021 4:22 PM EDTCantor Fitzgerald analyst Alethia Young lowered the price target on Biogen (NASDAQ: BIIB) to $327.00 (from $427.00) while maintaining a Neutral rating.
... MoreBiogen (BIIB) to Report Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS at American Neurological Association Annual Meeting
October 14, 2021 4:07 PM EDTBiogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), will be presented at the upcoming American Neurological Association (ANA) 2021 virtual meeting, October 17-19, 2021.
... More